Latest Breaking News On - Relapsed refractory lbcl - Page 1 : comparemela.com

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Mosunetuzumab mosunInternational prognostic indexClin oncolBlood marrow transplantAnn arborLargeb cell lymphomaPolatuzumab vedotinRelapsed refractory lbclRelapsed refractory largeb cell lymphomaOverall response rate